期刊
JOURNAL OF MATERIALS CHEMISTRY B
卷 9, 期 3, 页码 612-633出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0tb02139c
关键词
-
资金
- National Nature Science Foundation of China [31872756, 32071387]
- National Major Scientific and Technological Special Project for 'Significant New Drugs Development' [2016ZX09101031]
- Jiangsu Six Talent Peaks Program [JY-079]
- 'Double First-Class' University Project [CPU2018GY23, CPU2018GY26]
rHDL is a synthesized drug delivery nanoplatform with excellent biocompatibility and active-targeting ability, which improves the therapeutic effect of antitumor drugs.
rHDL is a synthesized drug delivery nanoplatform exhibiting excellent biocompatibility, which possesses most of the advantages of HDL. rHDL shows almost no toxicity and can be degraded to non-toxic substances in vivo. The severe limitation of the application of various antitumor agents is mainly due to their low bioavailability, high toxicity, poor stability, etc. Favorably, antitumor drug-loaded rHDL nanoparticles (NPs), which are known as an important drug delivery system (DDS), help to change the situation a lot. This DDS shows an outstanding active-targeting ability towards tumor cells and improves the therapeutic effect during antitumor treatment while overcoming the shortcomings mentioned above. In the following text, we will mainly focus on the various applications of rHDL in tumor targeted therapy by describing the properties, preparation, receptor active-targeting ability and antitumor effects of antineoplastic drug-loaded rHDL NPs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据